ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Dual-Target Therapy in Systemic Lupus Erythematosus
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first...
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first...
The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding...
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced the presentation of new data from...
Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have...
The National Medical Products Administration (NMPA) of China and the Danish Medicines Agency have signed...
NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...
HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that...
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered...
Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in...
Sino Medical Sciences Technology Inc., (SHA: 688108) a China-based medical device company, has announced that...
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the commencement of...
Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF),...
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...
The Center for Drug Evaluation under the National Medical Products Administration (NMPA) has issued the...
Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530),...
LINDIS Biotech GmbH, a German biotechnology company, has announced that the Committee for Orphan Medicinal...
The National Medical Products Administration (NMPA) has officially released the “Pilot Work Plan for Phased...
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...
China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has announced that it has...